# Eikon Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/eikon-therapeutics

- Industry: Biotechnology
- Headquarters: Millbrae, US
- Website: www.eikontx.com
- Total disclosed funding: $1B
- Latest round: Series D (Feb 14, 2025)
- Investors on record: 20

## About

Founded in 2019 and based in Hayward, CA, Eikon Therapeutics, Inc. is a drug discovery and development business that analyzes single-molecule protein behaviour in living cells using superior engineering and high-performance computers. Co-founded by  Robert Tjian, Luke Lavis, Xavier Darzacq and Eric Betzig, Eikon Therapeutics, Inc. has raised a total of USD 1.16 billion across 5 rounds of funding. In February 2025, Eikon Therapeutics, Inc. raised USD 350.7 million in series D funding. This round of funding values Eikon Therapeutics, Inc. at USD 1.52 billion post-money. The company offers a drug discovery platform that assesses the impact of chemical compounds on the mobility of protein molecules in a cell using super-resolution fluorescence microscopy technology. The firm specializes in using single-molecule tracking (SMT) throughout the whole drug discovery paradigm, enabling the development of pharmaceuticals. Eikon's technology's capacity to collect photos and assess the dynamic mobility of proteins. The new technique can be used in secondary assays, compound optimization against targets, high-throughput screens, and other stages of the drug development process. Eikon's target is to develop new therapies for previously unsolvable targets by merging protein dynamics with a wide range of drug discovery assay platforms. Eikon's multidisciplinary team focuses on biochemistry, cell biology, medicinal chemistry, pharmacology, and single-molecule tracking.

## Funding rounds

- Series D, Feb 14, 2025, $351M — General Catalyst Partners, Alexandria Venture Investments, The Column Group, StepStone, Lux Capital, Foresite Capital, AME Cloud Ventures, UC Ventures, E15 VC, T Rowe Price Advisory Services, Soros Capital Management LLC
- Series B, Dec 3, 2021, $518M — Schroders Capital, T Rowe Price, General Catalyst Partners, The Column Group, StepStone, Lux Capital, CPP Investment Board, Harel Insurance, Innovation Endeavors, Foresite Capital, Hartford Healthcare Endowment, Horizons Ventures, EcoR1 Capital, AME Cloud Ventures, UC Ventures, E15 VC, Soros Capital Management LLC, ADIA
- Series A, May 4, 2021, $103M — The Column Group, Lux Capital, Innovation Endeavors, Foresite Capital
- Series A, Sep 20, 2019, $48M — The Column Group, Lux Capital, Innovation Endeavors, Foresite Capital

## Investors

- The Column Group (https://capitalatlas.ai/funds/the-column-group) — Series A, Series B, Series D
- Lux Capital (https://capitalatlas.ai/funds/lux-capital) — Series A, Series B, Series D
- Innovation Endeavors (https://capitalatlas.ai/funds/innovation-endeavors) — Series A, Series B
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series A, Series B, Series D
- Schroders Capital (https://capitalatlas.ai/funds/schroders-capital) — Series B
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series B
- General Catalyst Partners (https://capitalatlas.ai/funds/general-catalyst-partners) — Series B, Series D
- StepStone (https://capitalatlas.ai/funds/stepstone) — Series B, Series D
- CPP Investment Board — Series B
- Harel Insurance — Series B
- Hartford Healthcare Endowment — Series B
- Horizons Ventures — Series B
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series B
- AME Cloud Ventures (https://capitalatlas.ai/funds/ame-cloud-ventures) — Series B, Series D
- UC Ventures (https://capitalatlas.ai/funds/uc-ventures) — Series B, Series D
- E15 VC (https://capitalatlas.ai/funds/e15-vc) — Series B, Series D
- Soros Capital Management LLC — Series B, Series D
- ADIA — Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series D
- T Rowe Price Advisory Services — Series D